Rajyalakshmi Luthra

Medicine & Life Sciences

1. Mutation 100%
2. High-Throughput Nucleotide Sequencing 78%
3. Neoplasms 54%
4. Acute Myeloid Leukemia 48%
5. B-Cell Chronic Lymphocytic Leukemia 26%
6. Genes 26%
7. Polymerase Chain Reaction 24%
8. Microsatellite Instability 24%
9. Cell-Free Nucleic Acids 23%
10. Survival 22%
11. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21%
12. Colorectal Neoplasms 19%
13. Hereditary Nonpolyposis Colorectal Neoplasms 17%
14. Myelodysplastic Syndromes 17%
15. Endometrial Neoplasms 17%
16. Philadelphia Chromosome 16%
17. Real-Time Polymerase Chain Reaction 16%
18. Protein-Tyrosine Kinases 16%
19. DNA 14%
20. Therapeutics 14%
21. Bone Marrow 14%
22. Carcinoma 14%
23. Karyotype 13%
24. Mantle-Cell Lymphoma 13%
25. Cytogenetics 13%
26. Anaplastic Large-Cell Lymphoma 13%
27. Imatinib Mesylate 13%
28. Molecular Pathology 12%
29. Non-Hodgkin's Lymphoma 12%
30. DNA Mismatch Repair 11%
31. Chromosome Aberrations 11%
32. Adenocarcinoma 10%
33. Capillary Electrophoresis 10%
34. Leukemia 10%
35. Precursor Cell Lymphoblastic Leukemia-Lymphoma 10%
36. Circulating Tumor DNA 10%
37. Fluorescence In Situ Hybridization 10%
38. Cell Biology 10%
39. Anaplastic Lymphoma Kinase 10%
40. Mutation Rate 10%
41. Residual Neoplasm 10%
42. GATA2 Deficiency 9%
43. Lymphoma 9%
44. Biomarkers 9%
45. Leukemia, Myeloid, Chronic Phase 9%
46. Primary Myelofibrosis 9%
47. INCB018424 9%
48. Paraffin 8%
49. Leukemia, Myelomonocytic, Chronic 8%
50. Blast Crisis 8%